We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

CPhI & P-MEC China Closes as the Chinese Domestic Market Continues to Expand

CPhI & P-MEC China Closes as the Chinese Domestic Market Continues to Expand

CPhI & P-MEC China Closes as the Chinese Domestic Market Continues to Expand

CPhI & P-MEC China Closes as the Chinese Domestic Market Continues to Expand

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CPhI & P-MEC China Closes as the Chinese Domestic Market Continues to Expand"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CPhI & P-MEC China, hosted by UBM EMEA and CCCMHPIE, and co-organized by UBM Sinoexpo held its most successful event yet at the Shanghai New International Expo Centre, (SNIEC) 24-26 June 2015.

This year marked the 15th anniversary of CPhI China, and a decade in partnership with P-MEC. Over the past 10+ years, this event has successfully grown in lieu with the rapidly expanding Chinese market, acting as a central hub for crucial networking and knowledge sharing opportunities - CPhI and the pharma industry in China are inseparable drivers of each other’s development.

As discussed, in the impending CPhI Insights Report on the Chinese market (to be released next week), unlike pharma manufacturing in the West, China’s growth is not solely dependent on increasing sales of finished formulations in highly regulated markets - the economic and cost advantages from large scale API batches are simply too strong to be resisted.

The increased interest in this market was reflected at the event, which delivered record numbers in both event scale and attendance for 2015. Over 2,600 global companies exhibited across the 150,000 square metre floor space and 64,000+ visitors were welcomed to CPhI & P-MEC China and concurrent event Fi Asia China (FiAC).

Over 70 onsite conferences and activities were hosted, covering numerous pressing topics ranging from contract services to environmental protection and clean technology. In particular, the ‘2nd P-MEC Summit’ and ‘International Summit for Pharmaceutical Packaging & Drug Delivery System’ achieved remarkable results and highlighted the important role P-MEC and Innopack China play in the industry.

The huge portfolio of content, exhibition halls and industry executives signifies why CPhI & P-MEC China is such a crucial event to the pharmaceutical industry. Jie Wang, Vice President at Zhejiang Huahai Pharmaceutical Co., Ltd, comments: “The main benefit for us is being able to meet with all the clients and suppliers at the same time. CPhI holds a unique advantage by being the perfect one stop of all our needs.”

As China’s domestic market continues to expand, CPhI & P-MEC China will increasingly update its offering and retain its vital stance as a must-attend event for industry executives from all over the world.

“After CPhI Worldwide, China is the longest running CPhI event and the second largest. With consistent, strong growth forecast for the China pharma market over the next decade, CPhI & P-MEC China remains as crucial as ever in providing an international platform for global pharma executives, manufacturers and suppliers to meet. The key to success for most international manufacturers operating in China is partnering with the right local company and acquiring local knowledge – CPhI is integral to this.

The past 15 years have brought concurrent progress to the event and wider industry and UBM EMEA will continue to uphold the trust of the industry as we look forward to the next 15 years with immutable enthusiasm.” Chris Kilbee, Group Director Pharma, UBM EMEA.